Two Studies Show The Connection Of Zofran And Birth Defects

by Terry Bryant

The link between Zofran and birth defects has only been known for a short time, which is alarming because the drug has been prescribed to pregnant women for many years. These prescriptions should have never been made, as the drug has never been approved for use by pregnant women. Regardless, GlaxoSmithKline, the drug’s manufacturer, has done an effective job of marketing it to doctors for off-label use. Recent research, though, has put the pharmaceutical juggernaut under fire, and it will likely face billions in claims before it is all done.

Two studies in particular have demonstrated the link between Zofran and birth defects. One, published by the Center for Birth Defects Research and Prevention, demonstrated twice the risk of cleft lip and palate in children exposed to the medication during development. The second involved a survey of 900,000 pregnant Danish women, and concluded that the medication also doubled the chances of heart malformations. These complications are severe and usually require expensive surgery to correct. And in some cases, heart malformations may go undetected until the child’s life is threatened by them.

GlaxoSmithKline has already had to pay out a $3 billion judgment to the Department of Justice for misleading and illegal marketing. Now, many families are filing suits against the company for its poor safety research and reckless marketing. Any family affected by the drug is encouraged to come forward and seek justice for their child’s suffering.